Point72 Asset Management, L.P.
· Exited
Change
−2.9M
Δ Own
−100.0%
Date
Q1 2026
OR
| Investor | Type | Est. change | Change | Δ Own | Date | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Point72 Asset Management, L.P.
· Exited
Change
−2.9M
Δ Own
−100.0%
Date
Q1 2026
|
Point72 Asset Management, L.P. | Exited· Q1 2026 | – | −2.9M | −100.0% | Q1 2026 | |||||
|
Aihc Capital Management Ltd
· New
Change
+2.5M
Date
Q1 2026
|
Aihc Capital Management Ltd | New· Q1 2026 | – | +2.5M | – | Q1 2026 | |||||
|
T. Rowe Price Associates
· Added
Change
+2.1M
Date
Q1 2026
|
T. Rowe Price Associates | Added· Q1 2026 | – | +2.1M | – | Q1 2026 | |||||
|
Siren, L.L.C.
· Added
Change
+2.0M
Date
Q1 2026
|
Siren, L.L.C. | Added· Q1 2026 | – | +2.0M | – | Q1 2026 | |||||
|
Venrock Adviser, LLC
· Reduced
Change
−1.4M
Date
Q1 2026
|
Venrock Adviser, LLC | Reduced· Q1 2026 | – | −1.4M | – | Q1 2026 | |||||
|
Braidwell LP
· New
Change
+1.1M
Date
Q1 2026
|
Braidwell LP | New· Q1 2026 | – | +1.1M | – | Q1 2026 | |||||
|
Woodline Partners LP
· Added
Change
+1.0M
Date
Q1 2026
|
Woodline Partners LP | Added· Q1 2026 | – | +1.0M | – | Q1 2026 | |||||
|
Orbimed Advisors LLC
· Reduced
Change
−948K
Date
Q1 2026
|
Orbimed Advisors LLC | Reduced· Q1 2026 | – | −948K | – | Q1 2026 | |||||
|
Defilade Capital Management, L.P.
· New
Change
+843K
Date
Q1 2026
|
Defilade Capital Management, L.P. | New· Q1 2026 | – | +843K | – | Q1 2026 | |||||
|
Viking Global Investors LP
· Reduced
Change
−748K
Δ Own
−11.4%
Date
Q1 2026
|
Viking Global Investors LP | Reduced· Q1 2026 | – | −748K | −11.4% | Q1 2026 | |||||
|
Barclays PLC
· Reduced
Change
−706K
Date
Q1 2026
|
Barclays PLC | Reduced· Q1 2026 | – | −706K | – | Q1 2026 | |||||
|
Paradigm Biocapital Advisors LP
· Reduced
Change
−700K
Date
Q1 2026
|
Paradigm Biocapital Advisors LP | Reduced· Q1 2026 | – | −700K | – | Q1 2026 | |||||
|
Sofinnova Investments, Inc.
· New
Change
+680K
Date
Q1 2026
|
Sofinnova Investments, Inc. | New· Q1 2026 | – | +680K | – | Q1 2026 | |||||
|
Pfizer Inc
· Reduced
Change
−596K
Date
Q1 2026
|
Pfizer Inc | Reduced· Q1 2026 | – | −596K | – | Q1 2026 | |||||
|
Candriam S.c.a.
· New
Change
+574K
Date
Q1 2026
|
Candriam S.c.a. | New· Q1 2026 | – | +574K | – | Q1 2026 | |||||
| Insider | Title | Type | Price | Qty | Value | Owned | ΔOwn | Trade date | Filed date | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Heyman Richard A.
· Director
Sell
−$4K
|
Heyman Richard A. | Director | Sell | $12.00 | −300 | −$4K | 213K | −0.1% | Jul 6, 2026 | Jul 8, 2026 | |||||||||
|
Piscitelli Dominic
· Officer
Sell
−$703K
|
Piscitelli Dominic | Officer | Sell | $13.51 | −52K | −$703K | 68K | – | Feb 24, 2026 | Feb 26, 2026 | |||||||||
|
Piscitelli Dominic
· Officer
2 operations
0
|
Piscitelli Dominic | Officer | 2 operations | $4.36 | 0 | – | 144K | – | Feb 24, 2026 | Feb 26, 2026 | |||||||||
N
A
M
G
A
A
176 reporting institutions disclosed ORIC position changes in the Q1 2026 snapshot.
For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.
An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.
Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.
Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.
A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.